Bioqual (OTCMKTS:BIOQ) Shares Down 7.1% – Time to Sell?

Bioqual Inc. (OTCMKTS:BIOQ) shares fell 7.1% on Thursday . The company traded as low as $32.50 and last traded at $32.50. 1,272 shares traded hands during trading, an increase of 782% from the average session volume of 144 shares. The stock had previously closed at $35.00.

Bioqual Stock Down 7.1%

The stock has a market capitalization of $28.93 million, a price-to-earnings ratio of -30.09 and a beta of -0.21. The business’s 50-day moving average is $35.73 and its two-hundred day moving average is $37.23.

Bioqual (OTCMKTS:BIOQ) last posted its quarterly earnings results on Tuesday, April 21st. The company reported ($0.84) earnings per share for the quarter. The business had revenue of $9.84 million for the quarter. Bioqual had a negative return on equity of 2.69% and a negative net margin of 2.27%.

Bioqual Company Profile

Bioqual, Inc is a U.S.-based contract research organization specializing in preclinical immunology and pharmacology services for the biopharmaceutical industry. The company offers a range of in vivo and in vitro testing solutions designed to support vaccine development, immuno-oncology programs and other therapeutic modalities. Bioqual’s service portfolio encompasses assay development, safety and efficacy studies, biomarker analysis and specialized immunogenicity assessments.

Leveraging proprietary humanized animal models and nonhuman primate research platforms, Bioqual helps clients evaluate biological activity, toxicity and pharmacokinetics of investigational compounds.